NCT02279394 - E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 11, 2014

Primary Completion Date

December 12, 2018

Study Completion Date

January 26, 2022

Conditions

Smoldering MyelomaSmoldering Multiple Myeloma

Interventions

DRUG

Elotuzumab

10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8

DRUG

Lenalidomide

25 mg Oral; Days 1-21 days Cycles 1-24

DRUG

Dexamethasone

40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8

Trial Locations (9)

University of Maryland, Baltimore

Levine Cancer Institute, Charlotte

Barbara Ann Karmanos Cancer Institute, Detroit

University of Chicago, Chicago

Colorado Blood Cancer Institute, Denver

St Francis Hospital and Medical Center, Hartford

Eastern Maine Medical Center, Brewer

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston